Cognitive Support, Circulation, and Tinnitus

Evidence Review

Systematic Evidence: Cognitive Impairment and Dementia

The 2017 Yuan et al. overview in Journal of Ethnopharmacology synthesized 12 systematic reviews and meta-analyses covering ginkgo biloba for dementia treatment. [1] The pooled conclusion across these reviews was that GbE produces beneficial effects over placebo on:

• Cognitive performance (measured by ADAS-Cog, MMSE, and similar instruments)
• Activities of daily living
• Clinical global impression (CGI) — a holistic clinician-rated measure of patient function

These benefits were consistently observed at doses above 200 mg/day and in trials lasting at least 22 weeks. The authors note that EGb 761 at 240 mg/day is the formulation with the strongest and most consistent evidence — older trials using 120 mg/day have less consistent results.

Updated RCT Review: Evidence Stratification by Population

The 2020 Liu et al. review in Frontiers in Pharmacology [2] specifically examined whether cognitive benefits differ by population — healthy adults versus those with MCI or dementia. Key findings:

• For healthy adults: the majority of RCTs found no significant cognitive benefit from ginkgo supplementation. Effect sizes where present were small and inconsistent.
• For mild cognitive impairment: multiple trials showed improvement in cognitive test scores and daily functioning at 240 mg/day EGb 761 over 24 weeks.
• For Alzheimer's dementia: some trials showed cognitive stabilization or modest improvement, but the evidence base is more variable.

The review concluded that EGb 761 may slow cognitive decline in the early symptomatic stages of dementia, while not meaningfully improving cognition in people who are already cognitively healthy.

The GEM Study: Prevention in Healthy Elderly

DeKosky et al. 2008 in JAMA [3] represents the largest and most rigorous trial of ginkgo for dementia prevention. Design details:

• n = 3,069 community-dwelling adults, age 75+
• Randomized, double-blind, placebo-controlled
• Intervention: 120 mg EGb 761 twice daily (240 mg/day total)
• Duration: median 6.1 years (range 3.5–8 years)
• Primary outcomes: incident all-cause dementia and Alzheimer's dementia

Results: Ginkgo biloba did not reduce the incidence of dementia (HR 1.12, 95% CI 0.94–1.33, p=0.21) or Alzheimer's disease (HR 1.16, 95% CI 0.97–1.39, p=0.11) compared to placebo. There was also no significant difference in the rate of cognitive decline among those who did not develop dementia.

Interpretation: This definitively rules out ginkgo as a preventive agent for dementia in cognitively normal elderly adults at standard doses. It does not speak to whether ginkgo may slow progression once mild cognitive impairment has emerged — the GEM study enrolled people who were cognitively normal at baseline.

Peripheral Circulation: Cochrane Review

Nicolaï et al.'s 2013 Cochrane review [4] on ginkgo for intermittent claudication (leg pain from reduced blood flow during walking) included 14 randomized trials with 739 participants. The pooled analysis found:

• Pain-free walking distance improved by an average of 64.5 metres on a flat treadmill
• Maximum walking distance showed a small non-significant trend toward improvement
• Authors' conclusion: there is no evidence that ginkgo has a clinically significant benefit for peripheral arterial disease

The hemodynamic and antioxidant effects of ginkgo are real, but may not translate into functional improvements large enough to matter to patients with established claudication. This illustrates a common gap between mechanism and clinical impact.

Tinnitus: Systematic Review and RCT

Von Boetticher's 2011 systematic review [5] of ginkgo for tinnitus found three trials in which tinnitus was the primary complaint (rather than a secondary outcome in dementia trials) that demonstrated efficacy for EGb 761. The review noted that tinnitus related to cochlear microcirculatory impairment represents the most plausible mechanism for benefit — and that trials mixing etiologically heterogeneous tinnitus populations tend to show weaker results, diluting signals from patients who are most likely to respond.

The 2018 Procházková et al. RCT [6] provided more controlled evidence: 197 patients with chronic tinnitus were randomized to EGb 761 120 mg twice daily or pentoxifylline 400 mg twice daily (an active comparator rather than placebo) over 12 weeks. Both groups improved on tinnitus loudness (Tinnitus Handicap Inventory) and anxiety scores (HADS). No statistically significant difference between groups was found, suggesting ginkgo is a reasonable alternative to standard pharmacotherapy for this indication.

Limitations of the tinnitus literature: placebo response in tinnitus trials is notoriously high; most trials are short (12 weeks or less); and the heterogeneity of tinnitus causes makes sub-group identification important for future research.

Evidence Strength Summary

Indication	Evidence Strength	Notes
MCI / early dementia (240 mg/day, 24+ weeks)	Moderate	Multiple systematic reviews positive; needs more large RCTs
Dementia prevention in healthy elderly	Negative	Large GEM trial null result
Tinnitus (EGb 761)	Low-moderate	Positive mechanistic rationale; clinical trial quality variable
Peripheral artery disease	Low	Statistically significant but not clinically meaningful per Cochrane
Cognitive enhancement in healthy adults	Negative	Most RCTs null

Overall, the strongest and most credible use case for ginkgo biloba is supporting cognitive function in people who already have mild cognitive impairment, using the standardized EGb 761 extract at 240 mg/day over several months. The evidence does not support its use as a preventive supplement for healthy adults, but it represents a reasonable adjunct approach for those experiencing early cognitive changes or tinnitus with vascular involvement.